Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05824273 · ClinicalTrials.gov registry record · NA
The INSPIRE-Lung Study
A NA study, sponsored by Hackensack Meridian Health.
- Completed
- Registry status
- NA
- Development phase
- 512
- Enrollment target
NCT05824273: Completed NA study, sponsored by Hackensack Meridian Health.
NCT05824273 is a NA study that has completed, run by Hackensack Meridian Health. The registered enrollment target is 512 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (64% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05824273, a NA study, has completed, sponsored by Hackensack Meridian Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 512 participants
- Enrollment target
Study Summary
LungTalk and leveraging Facebook-targeted Advertisement (FBTA) addresses the call to develop and test multi-level, cancer communication interventions using innovative methods and designs. The study's long term goal is to increase lung cancer screening uptake among appropriate, high-risk individuals nationwide.
Primary Outcome
Leveraging a well-established, social media-based platform (Facebook) to target screening-eligible individuals in the community. This will be measured by the total number of people who saw the FBTA at least once.
Interventions
- BEHAVIORAL LungTalk
- BEHAVIORAL Non-tailored intervention - Standard of practice
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 512 participants |
| Start Date | 2023-08-02 |
| Est. Completion | 2024-07-30 |
| Phase | NA |
What the finished NCT05824273 record still lists
NCT05824273 is an interventional study that assigns participants to a tested intervention. The registered 512 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (64% lower).
The record links to 0 conditions, and to 2 interventions - of which LungTalk is the first listed.
NCT05824273 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05824273 about?
NCT05824273 is a clinical study titled "The INSPIRE-Lung Study". LungTalk and leveraging Facebook-targeted Advertisement (FBTA) addresses the call to develop and test multi-level, cancer communication interventions using innovative methods and designs. The study's long term goal is to increase lung cancer screening uptake among appropriate, high-risk individuals ...
What is the current status of trial NCT05824273?
This trial is currently completed. It is a NA study. The enrollment target is 512 participants. The study started on 2023-08-02. Estimated completion is 2024-07-30.
What interventions are being tested in trial NCT05824273?
The interventions under investigation include: LungTalk (BEHAVIORAL), Non-tailored intervention - Standard of practice (BEHAVIORAL).
Who is sponsoring clinical trial NCT05824273?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05824273's enrollment target sits among peer trials
512 192nd of 2000 higher than 1,809 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05005403 · 512 participants · Phase 1
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab
- NCT05337410 · 512 participants · NA
YES: Innovative Discussion for Engagement, Achievement, and Service
- NCT06096259 · 512 participants · Phase 2
Preventing Injured Knees From osteoArthritis: Severity Outcomes
- NCT05691244 · 514 participants · Phase 3
Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI